Roche and Ventana Reach Definitive Merger Agreement
BASEL, Switzerland and TUCSON, Ariz., Jan. 22 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems ("Ventana") (Nasdaq: VMSI) today announced that they have signed a definitive merger agreement. Under the terms of the agreement, Roche will increase the purchase price in the tender offer for Ventana common shares to $89.50 per share in cash (or an aggregate of approximately $3.4 billion on a fully diluted basis), and Ventana's Board of Directors will recommend that Ventana's shareholders tender their shares to Roche. The merger agreement has been approved by the boards of Ventana and Roche. This offer represents a premium of 4.9% to Ventana's closing price on January 18, 2008, a 19.3% premium to Roche's initial offer on June 27, 2007, and a 72.3% premium to Ventana's closing price on June 22, 2007 (the last trading day prior to the announcement of Roche's initial offer). The acquisition of Ventana, a leader in the fast-growing histopathology (tissue-based diagnostics) segment, will allow Roche to broaden its diagnostic offerings and complement its world leadership in both in-vitro diagnostic systems and oncology therapies.
Under the terms of the merger agreement, Roche will amend its existing
tender offer to acquire all of the outstanding common shares of Ventana to
reflect the terms of the merger agreement. The amended offer will increase
the offer price to $89.50 per share in cash, expire at 7:00 p.m., New York
City time on Thursday, February 7, 2008 and be subject to, among other
things, the conditions that there are validly tendered and not withdrawn,
|SOURCE Roche; Ventana Medical Systems|
Copyright©2008 PR Newswire.
All rights reserved